Anteris Technologies Global Corp., a structural heart company, discovers, develops, and commercializes medical devices to enhance the quality of life for patients with aortic stenosis. Its lead product candidate is the DurAVR transcatheter heart valve system, a novel transcatheter aortic valve for the treatment of aortic stenosis that is shaped to mimic the performance of a healthy human aortic valve. The company also devlops ADAPT anti-calcification tissue, an anti-calcification preparation that transforms xenograft tissue into durable bioscaffolds that are used to mimic human tissue for surgical repair in multiple settings, including aortic valve replacement; and ComASUR delivery system, a physician-developed balloon expandable delivery system that contains a reinforced steerable catheter for a precise deflection through the heart anatomy in a controlled manner to avoid damage to the aorta. Anteris Technologies Global Corp. was incorporated in 1999 and is based in Toowong, Australia.

Employees - 136, CEO - Wayne Geoffrey Paterson, Sector - Healthcare, Country - AU, Market Cap -

Altman ZScore(max is 10): -9.72, Piotroski Score(max is 10): 4, Working Capital: $18873000, Total Assets: $39878000, Retained Earnings: $-319086000, EBIT: -64933491, Total Liabilities: $15846000, Revenue: $2479093

AryaFin Target Price - $0.46 - Current Price $ - Analyst Target Price $